Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
7.075 USD | +2.53% | +1.94% | +1.07% |
02/04 | HC Wainwright Trims KALA BIO's Price Target to $21 From $22, Keeps Buy Rating | MT |
29/03 | KALA BIO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.07% | 19.43M | |
+29.49% | 684B | |
+30.34% | 568B | |
-3.98% | 361B | |
+17.70% | 329B | |
+4.23% | 284B | |
+16.21% | 240B | |
+9.66% | 208B | |
-6.83% | 200B | |
+7.17% | 166B |
- Stock Market
- Equities
- KALA Stock
- News KALA BIO, Inc.
- Kala Pharmaceutical to Proceed with Corneal Epithelial Defect Trial After Positive Safety Data in Cohort 1